Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

ROCHE HOLDING LTD.
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 394 M
EBIT 2017 18 161 M
Net income 2017 11 138 M
Debt 2017 10 106 M
Yield 2017 3,53%
Sales 2018 55 472 M
EBIT 2018 19 140 M
Net income 2018 12 335 M
Debt 2018 5 739 M
Yield 2018 3,70%
P/E ratio 2017 18,18
P/E ratio 2018 16,69
EV / Sales2017 4,13x
EV / Sales2018 3,90x
Capitalization 210 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
11/21Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
02:17p CHUGAI PHARMACEUTICAL : Bispecific Antibody Emicizumab Meets Primary Endpoint in..
02:17p ROCHE : Genentech's Hemlibra Significantly Reduced Bleeds in Phase III Study in ..
02:17p ROCHE : Phase III IMpower150 Study Showed Genentech's Tecentriq and Avastin Plus..
11:12a ROCHE : Lung cancer data gives Roches Tecentriq a boost
09:13a ROCHE : announces acquisition of lab technology firm Viewics
05:39a Illumina Wins UK Patent Suit Against Premaitha Health, Ariosa Diagnostics
11/21 ROCHE : Federal Contracts Awarded by Federal Agencies in South Dakota (Nov. 21)
11/21 CHUGAI PHARMACEUTICAL : HEMLIBRA® Receives the World's First Regulatory Approval..
11/21 FOUNDATION MEDICINE : Reports Summarize Breast Cancer Findings from Foundation M..
11/21 ROCHE : FDA approves Roche's Hemlibra for haemophilia A with inhibitors
More news
Sector news : Pharmaceuticals - NEC
06:07p European shares retreat on euro bounce; UK flat after budget
05:56p FTSE gets sterling boost, land purchase threat dents housebuilders
09:50a U.S. FDA approves first two-drug HIV regimen in win for GSK
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/21 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 272  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.212 522
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014